Bioventix PLC (LON:BVXP - Get Free Report) crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 2,734.67 ($37.03) and traded as low as GBX 2,600 ($35.20). Bioventix shares last traded at GBX 2,700 ($36.56), with a volume of 1,989 shares traded.
Bioventix Stock Down 1.1%
The firm's 50 day simple moving average is GBX 2,734.67 and its 200 day simple moving average is GBX 2,888.37. The company has a market capitalization of £139.76 million, a PE ratio of 17.26 and a beta of 0.35.
Bioventix (LON:BVXP - Get Free Report) last issued its earnings results on Monday, March 31st. The biotechnology company reported GBX 72.27 ($0.98) earnings per share (EPS) for the quarter. Bioventix had a net margin of 59.51% and a return on equity of 69.09%. As a group, sell-side analysts predict that Bioventix PLC will post 166.3066955 EPS for the current fiscal year.
Bioventix Cuts Dividend
The business also recently announced a dividend, which was paid on Friday, April 25th. Stockholders of record on Thursday, April 10th were paid a dividend of GBX 70 ($0.95) per share. This represents a dividend yield of 2.95%. The ex-dividend date of this dividend was Thursday, April 10th. Bioventix's dividend payout ratio is currently 102.19%.
Insider Activity
In other news, insider Bruce Hiscock acquired 31 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The stock was purchased at an average cost of GBX 2,632 ($35.63) per share, for a total transaction of £815.92 ($1,104.68). Insiders own 8.02% of the company's stock.
About Bioventix
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
